Intelligent blood sugar lowering
The advantage of Novoca? compared with traditional oral hypoglycemic drugs and insulin is first reflected in its hypoglycemic mechanism: GLP-1 is a peptide synthesized by intestinal cells, which can "press according to the level of glucose in the body". "Need" to regulate insulin secretion is like installing a "switch" on the pancreas. When the blood sugar in the body is too high, it turns this switch "on" to release insulin; when the blood sugar reaches the normal range, it "turns off" the switch to keep the blood sugar in a stable range and reduce the risk of hypoglycemia. to the lowest.
Protect beta cells
The main advantage of Novoli? is also reflected in its ability to protect the function of pancreatic beta cells. The gradual failure of β-cell function is the "culprit" that leads to the continuous progression of diabetes. Existing oral hypoglycemic drugs are unable to protect β-cell function and cannot prevent the further development of diabetes. The LEAD study, conducted in more than 4,000 diabetic patients in more than 40 countries around the world, has proven that Novoli? can improve the quantity and quality of insulin secretion from beta cells, thereby potentially delaying the progression of diabetes.
Only needs to be taken once a day
In addition to its excellent performance in lowering blood sugar, reducing hypoglycemic events, and protecting beta cell function, Novoli? can also reduce body weight. At the same time, it also has advantages in reducing the risk of cardiovascular disease due to its ability to lower systolic blood pressure. This undoubtedly brings unexpected "surprises" to patients with type 2 diabetes. In addition, Novoli? provides maximum treatment flexibility. It only needs to be administered once a day and can be administered at any time of the day without being restricted by meal times, making it most convenient for patients to take medication.